Toripalimab (Anti-PDCD1 / PD-1 / CD279) | PD-1/PD-L1 antibody

Toripalimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody targeting PD-1. It has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. 147.3 KD.

Purity & Quality Control

Batch: A308201 Purity: 99% Protein concentration: 3.41mg/ml Endotoxin Level: ＜1EU/mg

99

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description	Toripalimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody targeting PD-1. It has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. 147.3 KD.

References
[1] Zhang L, et al. Front Immunol. 2022 Jan 12;12:730666.

References

[1] Zhang L, et al. Front Immunol. 2022 Jan 12;12:730666.

Product Details

CAS No.	1924598-82-2
Isotype	Human IgG4SP
Source	CHO
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field